

## Special Issue

# Genetics and Therapy of Neuromuscular Disorders

### Message from the Guest Editor

In recent years, the fields of genetics and gene therapy of neuromuscular diseases have undergone a strong expansion. Currently, innovative therapies capable of modifying the natural history of the disease are being found and developed for pathologies for which no type of treatment had been previously available. This is why it is important to increase and continue this important line of research. I invite you to share your research in this area with the scientific community.

---

### Guest Editor

Dr. Alessandro Orsini

Pediatric Neurology Unit Maternal and Child Department, University Hospital of Pisa, 56126 Pisa, PI, Italy

---

### Deadline for manuscript submissions

closed (15 November 2023)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/173459](https://mdpi.com/si/173459)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))